By creating mutations in the Burkholderia mallei ATCC 23344 animal pathogen-like type III secretion system (TTSS), this study analyzes the correlation between type III secretion and the pathogenicity of ATCC 23344 in vivo. Mutagenesis demonstrated that a functional TTSS was required for the full pathogenicity of ATCC 23344 in the BALB/c mouse and Syrian hamster models of infection. However, vaccination with each mutant failed to elicit a protective immunity against challenge with wild-type ATCC 23344.
Salmonella inv/spa/prg and Shigella ipa/mxi/spa systems (thoroughly reviewed in reference 4). Interestingly, multiple sequence gaps ranging from 1 to 90 bp were identified when the B. pseudomallei K96243 (http://www.sanger.ac.uk/) and ATCC 23344 TTSS loci were aligned with each other and compared at the nucleotide level ( Fig. 1) . Many of the sequence gaps are flanked by simple sequence repeats, which may provide a mechanism for the addition or removal of amino acids from the encoded proteins. A majority of the sequence gaps (99%) occurring within putative ORFs did not induce frameshift mutations because they occurred in multiples of 3 bp. In contrast, sequence gaps not divisible by 3, which generate frameshifts, were primarily present within intergenic regions. However, located in the 5Ј region of the bsaX allele ( Fig. 1) , a 1-bp deletion was identified, which conceivably causes a frameshift resulting in a truncated protein in B. mallei. These results suggest the BsaX protein may not be an essential component of the Burkholderia TTSS.
Bacterial strains, plasmids, and PCR primers used in this study are listed in Table 1 . Primers for the bsaQ and bsaZ (13) genes were designed in silico using the nucleotide sequence of the B. mallei ATCC 23344 TTSS. Disruption of these alleles, which are essential components of the secretion apparatus, would likely exert a polar effect on the ATCC 23344 TTSS and disrupt effector molecule secretion. Genomic DNA for PCR amplification was purified using the MasterPure DNA purification kit according to the manufacturer's instructions (Epicentre Technologies, Madison, Wis.). Internal gene fragments for creating disruption cassettes were PCR amplified using the following conditions: one cycle at 94°C for 5 min; 30 cycles at 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s; followed by a final 7-min extension at 72°C. Internal gene amplicons were subcloned into pCR2.1-TOPO (Invitrogen, Carlsbad, Calif.) and transformed into One Shot chemically competent Escherichia coli cells (Invitrogen). Integration cassettes were made by digesting pCR2.1-TOPO containing the bsaQ and bsaZ internal gene amplicons with EcoRI (New England Biolabs, Beverly, Mass.) followed by subcloning (Fast-Link DNA ligation kit; Epicentre Technologies) into the suicide vector pTSV3 digested with EcoRI. Ligations were electroporated into E. coli SM10 (11) and mobilized into ATCC 23344 using methods described by DeShazer et al. (3) . To confirm site-specific integration (single-crossover mutants), PCR parameters modified from those described above, specifically increasing the extension to 4 min, were employed using gene-specific primers flanking the bsaQ and bsaZ alleles (Table 1 ). To confirm the stability of our merodiploids in vitro, organ extracts 30 days postexposure were plated on Luria-Bertani plates (Fisher Scientific, Pittsburgh, Pa.) containing 4% glycerol (vol/vol) (LBG) with and without antibiotic. Whole-body aerosol exposures of 6-to 8-week-old female BALB/c mice (National Cancer Institute, Frederick, Md.) using ATCC 23344, RD01 (bsaQ::pTSV3), and RD02 (bsaZ::pTSV3) were performed as described by Jeddeloh et al. (5) . A relative dose of 1.0 ϫ 10 4 CFU was targeted for each strain, representing approximately 10 times the 50% lethal dose (LD 50 ) (5) . To analyze the pathogenicity of ATCC 23344, RD01, and RD02, bacterial loads within the spleen, liver, and lungs of BALB/c mice challenged with each strain (doses were identical to those previously described) were assayed over a 5-day period postexposure. Briefly, one mouse from each experimental group was euthanized (CO 2 chamber) on each of days 1 to 5, and the organs were extracted, homogenized in sterile phosphate-buffered saline, serially diluted, and plated on LBG. In addition, to determine if animals were chronically infected with RD01 and RD02, a single animal was euthanized 30 days postchallenge and organs were processed as described above. Figure 2B shows the bacterial loads of ATCC 23344, RD01, and RD02 within the lungs of BALB/c mice. Bacterial counts for ATCC 23344 progressively increased over the 5-day course of analysis and peaked at day 4, with an average load of 2.4 ϫ 10 6 CFU/g of homogenized tissue. Organ loads within the liver and spleen spiked at day 5 with an enumerated concentration of 5.8 ϫ 10 5 and 3.5 ϫ 10 5 CFU/g of organ, respectively ( Fig.  2C and D) . Due to the animal mortality of groups infected with wild-type ATCC 23344, organ assays were not possible at day 30. In comparison, recovery of RD01 and RD02 within the lungs of challenged mice was markedly reduced in contrast to (Fig. 2B) . Both RD01 and RD02 were cleared from the lungs at days 2 and 3 postexposure, respectively. Interestingly, animals challenged with RD01 contained no recoverable organisms from the liver or spleen at days 2 to 30 ( Fig. 2C and D) . In contrast, at days 2 and 5, the livers of the experimental group receiving RD02 contained 2.9 ϫ 10 1 CFU/g of organ tissue. Unlike ATCC 23344 and RD01, RD02 caused a biphasic course of infection and trophism for the liver and spleen was observed. At days 3 and 30, the livers of mice infected with RD02 were sterile compared to the spleen, which contained 7.3 ϫ 10 3 CFU/g of homogenized tissue at day 30 (Fig. 2D) . The stability of each merodiploid was analyzed from lung, liver, and spleen samples (30 days postexposure) by plating extracts on nonselective LBG. As anticipated, vector integration in vivo was stable without the presence of trimethoprim (data not shown).
To determine if RD01 and RD02 provided protection against wild-type ATCC 23344, experimental groups exposed to RD01 and RD02 were rechallenged by aerosol with each corresponding mutant at day 21. Following this booster, on day 42 mice were aerosolized with 1.7 ϫ 10 5 CFU of ATCC 23344 (100 times the LD 50 ). Unfortunately, neither RD01 nor RD02 conferred protection against challenge with wild-type ATCC 23344. These results could have been the consequence of the dose of ATCC 23344 delivered. For RD01, these findings were consistent with the observed rapid clearance from the lungs of infected animals (Fig. 2B) . However, these results were surprising for RD02, which persisted in the liver for several days postchallenge at concentrations conceivably sufficient to generate an adequate immunological response (Fig. 2C) .
Clinical manifestations, such as fur ruffling and animal hud- Five animals for each 10-fold dilution series were used, and the LD 50 was determined at day 4 as described by Reed and Muench (10) . The relative LD 50 for ATCC 23344 was Ͻ13 CFU, in contrast to Ͼ10 6 CFU and Ͼ10
5 CFU for RD01 and RD02, respectively. These findings definitively illustrate that TTS is crucial for the pathogenicity of ATCC 23344.
In addition to analyzing the organ loads of infected animals and determining the LD 50 s, the immunoglobulin G (IgG) titer against RD01 and RD02 was assayed 30 days postchallenge. IgG titers for each strain, in one animal from the ATCC 23344, RD01, and RD02 groups used for organ load analysis, were determined using an enzyme-linked immunosorbent assaybased technique described by Waag et al. (14) . Positive control ATCC 23344 antigen was prepared by harvesting an overnight culture of ATCC 23344 grown in glycerol (4% [vol/vol])-tryptone broth (Fisher Scientific). The cellular pellet was resus- pended in Hanks balanced salt solution, irradiated at 2.1 Mrads, washed three times in Hanks balanced salt solution, and resuspended in sterile water to yield a 1-mg/ml stock. An assayable immunological response, expressed as the reciprocal of the highest dilution yielding a positive reaction, was observed for RD02 (800) and the ATCC 23344 positive control (12,500). However, the IgG titer of animals infected with RD01 was undetectable. These results are consistent with the observed rapid clearance, 48 h postexposure, of RD01 from the lungs (Fig. 2B ) of infected mice. The only virulence factor definitively shown to be essential for the pathogenicity of B. mallei is an extracellular capsule (3). Mutational analysis of the B. pseudomallei animal pathogenlike TTSS, using in vitro techniques, demonstrated that the TTSS is required for intracellular replication within murine macrophage-like cells (J774.2), escape from endocytic vacuoles, and actin polymerization (13) . By creating specific mutations located within the bsaQ and bsaZ genes (Salmonella invA and spaS homologues), this investigation, despite only being able to analyze the organ loads from a single animal for each time point, suggests that TTS plays an essential role in the virulence of B. mallei ATCC 23344 in vivo. Further studies will be needed to identify putative effector molecules and decipher the complex molecular mechanisms associated with this animal pathogen-like TTSS. 
